Crescent Biopharma (CBIO) Common Equity (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Common Equity data on file, last reported at $183.8 million in Q1 2026.

• Quarterly Common Equity rose 709.55% year-over-year to $183.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183.8 million (up 709.55% YoY) and the FY2025 annual result came in at $203.0 million, up 1411.53% from the prior year.
• Common Equity declined to $183.8 million in Q1 2026 per CBIO's latest filing, from $203.0 million in the prior quarter.
• Across five years, Common Equity topped out at $203.0 million in Q4 2025 and bottomed at -$30.2 million in Q1 2025.
• The 5-year median for Common Equity is $48.1 million (2022), against an average of $62.4 million.
• Peak annual rise in Common Equity reached 9058.6% in 2025, while the deepest fall reached 204.32% in 2025.
• Tracing CBIO's Common Equity over 5 years: stood at $42.9 million in 2022, then dropped by 10.52% to $38.4 million in 2023, then slumped by 140.29% to -$15.5 million in 2024, then soared by 1411.53% to $203.0 million in 2025, then dropped by 9.44% to $183.8 million in 2026.
• Per Business Quant, the three latest CBIO Common Equity figures stand at $183.8 million (Q1 2026), $203.0 million (Q4 2025), and $116.6 million (Q3 2025).

Peer Comparison